Mobocertinib and Bevacizumab for Amivantamab-Refractory Lung Cancer With EGFR Exon 20 Insertion Mutation: A Case Report

Jaemin Kim; Youngjoo Lee

doi:10.1016/j.jtocrr.2023.100600

Mobocertinib and Bevacizumab for Amivantamab-Refractory Lung Cancer With EGFR Exon 20 Insertion Mutation: A Case Report

JTO Clin Res Rep. 2023 Nov 7;4(12):100600. doi: 10.1016/j.jtocrr.2023.100600. eCollection 2023 Dec.

Authors

Jaemin Kim¹, Youngjoo Lee^{1

2}

Affiliations

¹ Research Institute, National Cancer Center, Goyang, Republic of Korea.
² Division of Hematology and Oncology, Department of Internal Medicine, National Cancer Center, Goyang, Republic of Korea.

Abstract

Amivantamab is the first drug approved in EGFR exon 20 insertion-mutated NSCLC. Nevertheless, primary or secondary resistance to amivantamab is a frequent problem in clinical practice. We report a case of a patient with EGFR exon 20-mutated NSCLC who had primary resistance to amivantamab but was successfully treated by combining therapy of another EGFR exon 20 insertion-specific targeted drug mobocertinib and bevacizumab.

Keywords: Anti-angiogenesis; Case report; Drug resistance; EGFR exon 20 insertion; NSCLC; Targeted therapy.

Publication types

Case Reports